bpc 157 fda not approved warning panel is reviewing if 7 peptides should be made more accessible, an RFK Jr. priority FDA panel votes to place

Microdosing GLP-1/GIP therapies may help: Improve glycemic control, stable blood glucose levels, and blood pressure support Reduction in visceral fat and waist circumference Potential improvements in lipid profiles Reduce systemic inflammation markers associated with cardiometabolic disease Glycine amino acid that supports protein synthesis, endothelial function, and insulin sensitivity Reduce cardiovascular risk factors such as insulin resistance and central adiposity Whats Included Monthly compounded tirzepatide + glycine (Up to 3mg/week) or 2ml tirzepatide with B12 every 2 months with labs Personalized microdosing protocol Ongoing provider oversight with labs every six months This is not an FDA-approved microdosing regimen

So whos right

You can, but only if you intend to use the entire contents of the vial immediately after mixing

10.1038/s41401-020-0415-5 51 GuilliamsM.DutertreC

And it can impact their productivity by a few weeks to months

For broader context on multi-compound research designs, see our peptide research stacks overview